Skip to main content
    C

    Century Therapeutics Inc (IPSC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.50
    +0.12 (+8.70%)

    Market Cap: $249.88M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(12/22)
    Avg Surprise
    -30.24%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.11
    Range$-0.12 - $-0.08
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.12+10.8%
    60d ago$-0.12+10.8%
    30d ago$-0.110.0%
    7d ago$-0.110.0%
    Current$-0.11
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.07
    Range$-0.12 - $0.03
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.07---
    Sep 26EST
    		-$-0.11---
    Jun 26
    Reported Aug 12
    		$-0.17$-0.11-54.55%Miss+55.3%
    Mar 26
    Reported May 13
    		$-0.11$-0.17+35.29%Beat-112.4%
    Dec 25
    Reported Mar 12
    		$-0.25$-0.30+15.97%Beat+41.9%
    Sep 25
    Reported Nov 13
    		$-0.32$-0.38+15.79%Beat+13.5%
    Jun 25
    Reported Aug 14
    		$-0.38$-0.37-2.70%Miss+0.0%
    Mar 25
    Reported May 15
    		$0.89$-0.31+387.10%Beat+297.8%
    Dec 24
    Reported Mar 19
    		$-0.43$-0.45+4.44%Beat+33.8%
    Sep 24
    Reported Nov 5
    		$-0.37$-0.45+17.78%Beat+32.7%
    Jun 24
    Reported Aug 8
    		$-0.38$-0.50+24.00%Beat+22.4%
    Mar 24
    Reported May 9
    		$-0.45$-0.45+0.00%Beat+15.1%
    Dec 23
    Reported Mar 14
    		$-0.65$-0.55-18.18%Miss+71.4%
    Sep 23
    Reported Nov 9
    		$-0.55$-0.49-12.24%Miss-3.8%
    Jun 23
    Reported Aug 9
    		$-0.49$-0.54+9.26%Beat+9.3%
    Mar 23
    Reported May 11
    		$-0.53$-0.52-1.92%Miss-10.4%
    Dec 22
    Reported Mar 16
    		$-2.27$-0.59-284.75%Miss-845.8%
    Sep 22
    Reported Nov 10
    		$-0.53$-0.60+11.67%Beat-10.4%
    Jun 22
    Reported Aug 11
    		$-0.54$-0.50-8.00%Miss+72.0%
    Mar 22
    Reported May 16
    		$-0.48$-0.54+11.11%Beat+79.9%
    Dec 21
    Reported Mar 17
    		$-0.24$-0.48+50.00%Beat+74.8%
    Sep 21
    Reported Nov 10
    		$-0.48$-0.42-14.29%Miss+6.6%
    Jun 21
    Reported Aug 12
    		$-1.93$-0.38-407.89%Miss-
    Mar 21
    Reported Jun 21
    		$-2.39$-0.44-443.18%Miss-
    Dec 20
    Reported Mar 30
    		$-0.95$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-0.51$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.76EV/EBITDAN/A
    Price/FCF-3.49xFCF Yield-28.63%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-49.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio8.28xQuick Ratio8.28x
    Trading Statistics
    Beta1.67Avg Volume794.00K
    52-Week High$3.0452-Week Low$0.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.42
    SMA 20$1.58
    SMA 50$1.84
    SMA 200$2.09
    EMA 10$1.47
    EMA 20$1.57
    EMA 50$1.78
    EMA 200$1.83

    MACD

    Line: -0.14Signal: -0.14Hist: 0.00

    ADX

    ADX: 29.4+DI: 19.4-DI: 28.5

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down80.0
    PSAR$1.24

    Bollinger Bands

    Upper Band$1.95
    Lower Band$1.21
    %B Position4622%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    41.6

    Momentum Oscillators

    Stoch %K37.8
    Stoch %D32.9
    Williams %R-43.9
    ROC (10d)-6.8%
    Momentum-0.11
    CCI (20d)-53.1
    MFI (14d)31.6

    Volatility Measures

    ATR (14d)$0.12(8.1%)
    StdDev (20d)0.18
    Hist Vol85.9%(High)

    Volume Flow

    VWAP$1.46
    OBV54.3M
    AD Line-2.2M
    CMF (20d)-0.150

    Volume Metrics

    Avg Vol (20d)809.9K
    Vol Ratio1.1x
    VWMA (20d)$1.53

    Pivot Points

    R3$1.57
    R2$1.51
    R1$1.44
    Pivot Point$1.38
    S1$1.31
    S2$1.25
    S3$1.18

    Advanced Oscillators

    TSI-33.65
    Ultimate Osc54.3
    KST-256.21

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$109.16M$4.17M$791,000$771,000$855,000$268,000$148,000
    Cost of Revenue$0$0$3.55M$0$0$0$3.32M$0$0$0$22.30M$0
    Gross Profit$0$0$-3,550,000$0$0$109.16M$4.17M$791,000$771,000$855,000$268,000$148,000
    Operating Expenses$36.53M$23.68M$20.66M$36.12M$34.66M$34.99M$41.46M$35.58M$35.53M$32.16M$44.03M$35.77M
    R&D$19.59M$17.11M$19.70M$22.53M$26.86M$26.58M$29.38M$27.23M$27.22M$23.42M$23.30M$26.79M
    SG&A$5.79M$6.58M$955,000$6.83M$7.80M$8.41M$7.75M$8.35M$8.31M$8.74M$8.59M$8.99M
    Operating Income$-36,527,000$-23,684,000$-20,657,000$-36,124,000$-34,664,000$74.18M$-37,284,000$-34,789,000$-34,755,000$-31,309,000$-43,762,000$-35,626,000
    Interest Income$1.98M$2.02M$1.31M$1.60M$2.01M$2.42M$2.88M$3.31M$3.58M$3.24M$3.51M$3.49M
    Interest Expense$0$0$0$0$0$74.18M$0$0$0$0$0$0
    Income Before Tax$0$0$-19,245,000$-34,422,000$0$0$-34,296,000$-31,234,000$-31,185,000$-28,061,000$-40,267,000$-32,128,000
    Income Tax Expense$0$0$-68,000$0$0$0$1.77M$-8,000$22,000$1,000$-869,000$592,000
    Net Income$-34,550,000$-21,645,000$-19,177,000$-34,422,000$-32,541,000$76.56M$-36,071,000$-31,226,000$-31,207,000$-28,062,000$-39,398,000$-32,720,000
    EBITDA$-34,065,000$-20,871,000$-17,353,000$-33,405,000$-31,997,000$76.50M$-34,894,000$-32,562,000$-32,648,000$-29,187,000$-44,209,000$-32,264,000
    EBIT$-36,532,000$-23,664,000$-20,554,000$-36,027,000$-34,551,000$74.14M$-37,179,000$-34,539,000$-34,767,000$-31,298,000$-43,777,000$-35,614,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IPSC

    News

    Century Therapeutics presents CNTY-813 data: what it means for Century Therapeutics stock

    Century Therapeutics (IPSC) presented data on its CNTY-813 therapy, which maintained glycemic control for over 11 months in diabetic mice. The company anticipates filing an Investigational New Drug application...

    ad-hoc-news.de•10/15/26•Neutral

    Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London

    Century Therapeutics, Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026. The company...

    Yahoo! Finance Canada•10/14/26•Somewhat-Bullish

    Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London

    Century Therapeutics, Inc. (NASDAQ: IPSC) announced its attendance at the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026. The biotechnology company...

    GlobeNewswire•10/14/26•Somewhat-Bullish

    Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Glaukos (GKOS) and Praxis Precision Medicines (PRAX)

    Three healthcare companies, Century Therapeutics (IPSC), Glaukos (GKOS), and Praxis Precision Medicines (PRAX)...

    The Globe and Mail•10/7/26•Bullish

    Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Glaukos (GKOS) and Praxis Precision Medicines (PRAX)

    This article highlights bullish sentiments from three analysts regarding several healthcare companies. Edward Tenthoff of Piper Sandler reiterated a Buy rating for Century Therapeutics (IPSC) with a $4.00 price target....

    The Globe and Mail•10/7/26•Bullish

    IPSC Valuation and Fair Value

    P/E
    -1.8x
    P/FCF
    -3.5x
    P/B
    1.3x
    See GNG's fair value

    IPSC Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -49.6%
    FCF yield
    -28.6%

    IPSC Competitors

    CompanyTicker
    Inhibikase Therapeutics IncIKT
    BioAge Labs, IncBIOA
    Vanda Pharmaceuticals IncVNDA
    So-Young International IncSY
    OraSure Technologies IncOSUR
    Bicycle Therapeutics LtdBCYC
    EyePoint, IncEYPT
    SAB Biotherapeutics IncSABS

    Sector: Healthcare

    IPSC Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    1
    Buy
    3
    Hold
    1
    Sell
    0
    Strong Sell
    0

    IPSC Bull Case vs Bear Case

    Bull case

    • IPSC beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 80.0% of IPSC's analyst ratings are Buy or Strong Buy.

    Bear case

    • IPSC's quarterly revenue changed -100.0% year over year.

    IPSC Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    52.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.11
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About IPSC

    Does IPSC pay dividends?

    Century Therapeutics Inc (IPSC) does not currently pay a regular dividend.

    What is IPSC's market cap?

    Century Therapeutics Inc (IPSC) has a market capitalization of $249.88M with a current stock price of $1.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In